DCF Tool

ICLR

Icon Plc – Research and Development in Biotechnology
icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. we specialise in the strategic development, management and analysis of programmes that support clinical development - from compound selection to phase i-iv clinical studies. in a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. we have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. we are also an 'end-to-end'​ pharmacovigilance service provider and this includes post marketing surveillance activities too.
Analysis Results
Intrinsic Value $128.28
Latest Price $248.07
Relative Value 93% overvalued
Thoughts on this result? Let us know.
Ad
Cash Flow (Billions)
Analysis Parameters
%
%
%
New Ticker
Ad
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of 12.7%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 9.7%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of 12.7%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (billion) Present value (billion)
2023 0.62 0.565
2024 0.699 0.581
2025 0.788 0.596
2026 0.889 0.613
2027 1.0 0.629
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 13.2 billion. This corresponds to a present value of 7.55 billion.

Intrinsic Value Per Share

The total present value of the projected cash flows is 2.98 billion. Adding in the terminal value gives a total present value of 10.5 billion.

There are presently 82.2 million outstanding shares, so the intrinsic value per share is 128.28.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 3,229,066,000
Current Cash 290,481,000
Current Liabilities 2,690,601,000
Current Debt 55,150,000
Non-Cash Working Capital (NCWC) 303,134,000
Change in NCWC 539,648,000
EBIT 862,939,000
Tax Provision 59,411,000
Depreciation and Amortization 569,513,000
Capital Expenditure -142,160,000
Unlevered Free Cash Flow 1,739,154,260
Current Assets 2,941,198,000
Current Cash 753,925,000
Current Liabilities 2,478,937,000
Current Debt 55,150,000
Non-Cash Working Capital (NCWC) -236,514,000
Change in NCWC -373,515,000
EBIT 605,736,000
Tax Provision 41,334,000
Depreciation and Amortization 360,326,000
Capital Expenditure -93,750,000
Unlevered Free Cash Flow 370,082,109
Current Assets 2,102,978,000
Current Cash 842,034,000
Current Liabilities 1,123,943,000
Current Debt 0
Non-Cash Working Capital (NCWC) 137,001,000
Change in NCWC -136,430,000
EBIT 409,223,000
Tax Provision 47,875,000
Depreciation and Amortization 94,606,000
Capital Expenditure -51,055,000
Unlevered Free Cash Flow 264,900,867
Current Assets 1,624,980,000
Current Cash 569,937,000
Current Liabilities 1,131,252,000
Current Debt 349,640,000
Non-Cash Working Capital (NCWC) 273,431,000
Change in NCWC 9,632,000
EBIT 433,406,000
Tax Provision 51,133,000
Depreciation and Amortization 91,922,000
Capital Expenditure -50,645,000
Unlevered Free Cash Flow 432,413,548
Current Assets 1,330,183,000
Current Cash 455,761,000
Current Liabilities 610,623,000
Current Debt 0
Non-Cash Working Capital (NCWC) 263,799,000
Change in NCWC 89,287,000
EBIT 385,847,000
Tax Provision 41,958,000
Depreciation and Amortization 65,916,000
Capital Expenditure -48,397,000
Unlevered Free Cash Flow 448,251,609
Current Assets 1,101,018,000
Current Cash 360,448,000
Current Liabilities 566,058,000
Current Debt 0
Non-Cash Working Capital (NCWC) 174,512,000
Change in NCWC -28,453,000
EBIT 346,091,000
Tax Provision 46,569,000
Depreciation and Amortization 61,297,000
Capital Expenditure -44,717,000
Unlevered Free Cash Flow 285,089,001
Current Assets 957,958,000
Current Cash 260,587,000
Current Liabilities 494,406,000
Current Debt 0
Non-Cash Working Capital (NCWC) 202,965,000
Change in NCWC 100,233,000
EBIT 319,853,000
Tax Provision 37,993,000
Depreciation and Amortization 59,575,000
Capital Expenditure -42,601,000
Unlevered Free Cash Flow 396,575,960
Current Assets 864,433,000
Current Cash 189,901,000
Current Liabilities 571,800,000
Current Debt 0
Non-Cash Working Capital (NCWC) 102,732,000
Change in NCWC 37,584,000
EBIT 281,536,000
Tax Provision 39,311,000
Depreciation and Amortization 57,677,000
Capital Expenditure -49,730,000
Unlevered Free Cash Flow 287,377,339
Current Assets 819,507,000
Current Cash 216,000,000
Current Liabilities 538,359,000
Current Debt 0
Non-Cash Working Capital (NCWC) 65,148,000
Change in NCWC 33,725,000
EBIT 211,146,000
Tax Provision 30,248,000
Depreciation and Amortization 52,542,000
Capital Expenditure -32,779,000
Unlevered Free Cash Flow 233,128,128
Current Assets 853,428,000
Current Cash 320,836,000
Current Liabilities 501,169,000
Current Debt 0
Non-Cash Working Capital (NCWC) 31,423,000
Change in NCWC -28,673,000
EBIT 130,200,000
Tax Provision 18,053,000
Depreciation and Amortization 46,514,000
Capital Expenditure -29,488,000
Unlevered Free Cash Flow 99,105,677
Current Assets 663,748,000
Current Cash 190,230,000
Current Liabilities 413,422,000
Current Debt 0
Non-Cash Working Capital (NCWC) 60,096,000
Change in NCWC -19,241,000
EBIT 73,653,000
Tax Provision 11,801,000
Depreciation and Amortization 42,823,000
Capital Expenditure -30,791,000
Unlevered Free Cash Flow 53,513,828

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.